Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PolyTregs in Active Pemphigus
NCT03239470Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2017
- Primary completion
- Dec 2020
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CLBS03 in pemphigus vulgaris (PV) and pemphigus foliaceus (PF) (2 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Number of Significant Adverse Events at 52 weeks. Started Oct 2017; status: terminated.
02
Drugs
CLBS03
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on NCT03239470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03239470.